Skip to content
The Nexus
BUSINESSJul 2 · 11:00 UTCSCMP CHINAJulie Zhang

China AI drug-design deals swell as US scrutiny mounts

China's AI-driven drug-design firms are expanding globally through cross-border dealmaking, with out-licensing deals to major pharmaceutical companies reaching $75 billion in the first five months of 2026, up from zero before 2020. This growth occurs despite increasing US scrutiny of Chinese biotech firms.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned
ChinaplaceAI-driven drug-design firmstopicUnited StatesplaceHSBCorganizationLinda Shupersonbiotech firmsorganizationpharmaceutical companiesorganization
Spot something wrong with this article?Report a problem →
Forward this
Related Signal

Adjacent reporting